Data Based Cancer Research And Treatment Systems And Methods

Patent No. US11705226 (titled "Data Based Cancer Research And Treatment Systems And Methods") was filed by Tempus Labs on Oct 18, 2019.

What is this patent about?

’226 is related to the field of data management and analysis in healthcare , specifically focusing on cancer research and treatment. The patent addresses the challenges of efficiently capturing, storing, and utilizing diverse data types, including clinical records and genomic sequencing data, to improve cancer treatment planning. The background highlights the limitations of existing systems in handling the complexity and volume of cancer-related data, particularly the integration of genomic information with traditional clinical data.

The underlying idea behind ’226 is to create a multi-layered database system that optimizes data storage and access for different purposes. This involves capturing raw clinical data and genomic sequencing data, then transforming and structuring it into purpose-specific databases. The key insight is that a single database structure is not optimal for all uses, so the system employs a "data lake" for raw data, a "data vault" for structured data optimized for searching, and "data marts" for application-specific data.

The claims of ’226 focus on a method and system for storing and processing patient data , including clinical records and genomic sequencing data, to support cancer research and treatment. The independent claims cover the steps of obtaining clinical data, storing it in a semi-structured database, generating and storing genomic sequencing data, shaping the data into a structured format optimized for searching, storing the structured data in a second database, and then creating application-specific subsets of data in a third database. The claims also emphasize the role of an orchestration manager in initiating micro-service programs based on satisfied prerequisites.

In practice, the invention involves a workflow where clinical records and genomic data are first stored in a raw, semi-structured format in the data lake. Then, a series of micro-services process and transform this data, structuring it for efficient searching and analysis in the data vault. Finally, application-specific data marts are created to provide optimized data access for various user applications, such as those used by physicians or researchers. The orchestration manager ensures that these micro-services are executed in the correct order, based on data dependencies.

’226 differentiates itself from prior approaches by recognizing the need for purpose-built databases and a micro-service architecture to handle the diverse data types and analytical needs in cancer research and treatment. Unlike traditional systems that rely on a single, monolithic database, ’226 uses a layered approach with a data lake, data vault, and data marts, each optimized for a specific purpose. This allows for more efficient data access, faster analytics, and more rapid development of new applications and interfaces. The micro-service architecture also enables independent teams to work on different aspects of the system, facilitating rapid adaptation to new data types and research insights.

How does this patent fit in bigger picture?

Technical landscape at the time

In the late 2010s when ’226 was filed, at a time when systems commonly relied on machine learning for clinical concept identification, extraction, and prediction. Systems also commonly relied on genomic sequencing data to correlate genetic factors with treatment efficacy. Furthermore, systems commonly relied on structured clinical data for automated quality assurance testing.

Novelty and Inventive Step

Claims were rejected under 35 U.S.C. 101 as being directed to abstract ideas without significantly more. The specification was objected to. Certain claims were also objected to for containing informalities. The examiner indicated that claims 1-33 would be allowed if amended to overcome the outstanding rejections and objections.

Claims

This patent includes 89 claims, with independent claims numbered 1, 84, 85, and 86. The independent claims generally focus on methods for conducting genomic sequencing by storing clinical records and genomic sequencing data in databases, shaping the data, and using application programs to analyze the data. The dependent claims generally elaborate on and add detail to the steps and components recited in the independent claims.

Key Claim Terms New

Definitions of key terms used in the patent claims.

Term (Source)Support for SpecificationInterpretation
Application specific subset
(Claim 1, Claim 84, Claim 85, Claim 86)
“One other problem with existing cancer treatment efficacy databases and systems is that they are simply incapable of optimally supporting different types of system users. To this end, data access, views and interfaces needed for optimal use are often dependent upon what a system user is using the system for.”A portion of the system structured data selected from the second database and stored in a structure optimized for application program interfacing in a third database.
Clinical records data
(Claim 1, Claim 84, Claim 85, Claim 86)
“The present invention relates to systems and methods for obtaining and employing data related to physical and genomic patient characteristics as well as diagnosis, treatments and treatment efficacy to provide a suite of tools to healthcare providers, researchers and other interested parties enabling those entities to develop new cancer state-treatment-results insights and/or improve overall patient healthcare and treatment plans for specific patients.”Information related to a patient's medical history, cancer state, treatments, and treatment efficacy, obtained in its original form.
Genomic sequencing data
(Claim 1, Claim 84, Claim 85, Claim 86)
“With the advent of NGS it has become possible to accurately detect genetic alterations in relevant cancer genes in a single comprehensive assay with high sensitivity and specificity.”Data generated by a next generation genomic sequencer from DNA and whole-transcriptome RNA.
Next generation genomic sequencer
(Claim 1, Claim 84, Claim 85, Claim 86)
“Next generation sequencing involves using specialized equipment such as a next generation gene sequencer, which is an automated instrument that determines the order of nucleotides in DNA and RNA.”An automated instrument that determines the order of nucleotides in DNA and/or RNA.
System structured data
(Claim 1, Claim 84, Claim 85, Claim 86)
“Thus, what is needed is a system that is capable of efficiently capturing all treatment relevant data including cancer state factors, treatment decisions, treatment efficacy and exploratory factors (e.g., factors that may have a causal relationship to treatment efficacy) and structuring that data to optimally drive different system activities including memorialization of data and treatment decisions, database analytics and user applications and interfaces.”Data shaped from the clinical records and sequencing data, optimized for searching.

Litigation Cases New

US Latest litigation cases involving this patent.

Case NumberFiling DateTitle
3:25-cv-00621Mar 14, 2025Tempus Ai, Inc. V. Guardant Health, Inc.

Patent Family

Patent Family

File Wrapper

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Get instant alerts for new documents

US11705226

TEMPUS LABS
Application Number
US16657804
Filing Date
Oct 18, 2019
Status
Granted
Expiry Date
Mar 26, 2041
External Links
Slate, USPTO, Google Patents